Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 2/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15535810 | 0.98 | RAB9A (0.65) | L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL148956 | 0.94 | NPC1 (0.56) | L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL29953351 | 0.88 | NPC1 (0.51) | L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL20850172 | 0.86 | NPC1 (0.58) | L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL18579817 | 0.85 | KMT2A (0.50) | L3MBTL1RAB9ANPC1HTTALDH1A1 | |
| SCHEMBL9265040 | 0.84 | RAB9A (0.79) | L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL6707186 | 0.84 | RAB9A (0.79) | L3MBTL1RAB9ANPC1SMN1; SMN2HSD17B10 | |
| SCHEMBL21953980 | 0.82 | KDM1A (0.51) | L3MBTL1RAB9ANPC1GRM5KDM1A | |
| SCHEMBL2559523 | 0.82 | HRH3 (0.54) | RAB9ANPC1ALDH1A1 | |
| SCHEMBL384423 | 0.81 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20200131139-A1 | SMALL MOLECULE INHIBITORS OF BCL-2- ASSOCIATED DEATH PROMOTER (BAD) PHOSPHORYLATION | BANGALORE UNIVERSITY (IN) | 2020-04-30 | — | — | US | disclosed |
| WO-2018194520-A9 | SMALL MOLECULE INHIBITORS OF BCL-2-ASSOCIATED DEATH PROMOTER (BAD) PHOSPHORYLATION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-10-17 | — | — | WO | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | L3MBTL1 4518/4885RAB9A 2122/4885NPC1 4032/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | L3MBTL1 4518/4885RAB9A 2122/4885NPC1 4032/4885 |
| US-20200131139-A1 | SMALL MOLECULE INHIBITORS OF BCL-2- ASSOCIATED DEATH PROMOTER (BAD) PHOSPHORYLATION | BAD, BCL2, BCL2A1 | L3MBTL1 532/4885RAB9A 2687/4885NPC1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.